DJIA 17,678.70 6.10 0.03%
NASDAQ 4,771.76 13.88 0.29%
S&P 500 2,057.09 5.27 0.26%
market minute promo

MannKind Corp (NASDAQ: MNKD)

company name or ticker

MannKind: The Newest Bear Talking Point Is Absurd

Will Insulin Pricing Be MannKind Corporation's Downfall?

MannKind marketing partner Sanofi had to discount its Lantus insulin to get insurers to cover the drug.

Puma Is As Expensive As MannKind Is Cheap

Should MannKind's Shareholders Buy Al Mann's New Company?

Three Motley Fool analysts give their thoughts on whether or not to buy Al Mann's Second Sight on its initial public offering.

MannKind: Does Size Matter?

US IPO Weekly Recap: Burgers and bionic eyes gain over 100% as 9 companies go public

Sanofi's New Medicines Seminar: Implications For Afrezza

Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind

Second Sight sees double: Year's 6th IPO to soar 100% on day one

Sanofi: Recent Plunge Is A Buying Opportunity

See More Articles...